Efficacy and Safety on the Use of Bisphosphonates in Paediatrics

The investigators suppose that the impact of bisphosphonate therapy is beneficial on the bone during the growth period with few adverse events.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bone Fragile Adverse Events Bisphosphonate-Associated Osteonecrosis Bisphosphonate-Associated Osteonecrosis of the Jaw Bone Diseases Children Jaw Diseases Musculoskeletal Diseases Necrosis Osteonecrosis Pathologic Processes Pathological Conditions, Signs and Symptoms Stomatognathic Diseases

Age range

Up to 18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CHUNimes

Nîmes, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

be under 18 years of age
have been treated by intravenous bisphosphonates for primary or secondary osteoporosis

Exclusion criteria

be over 18 years of age

Treatment and study plan

no intervention, observational study

Other

No intervention, observational study

Primary outcomes

fracture rates

Time frame: 2 years

(numbers)
bone mineral density

Time frame: 2 years

(Z-score)
pain frequency

Time frame: 2 years

(never, occasional, regular)

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nīmes

Other

Registry information

Acronym: Bisphosphonate

Important dates

Study start: 2018
Primary completion: 2018
Study completion: 2018
First posted: Jul 9, 2019
Registry last updated: Jul 9, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed